Search

Background. Primary cutaneous lymphomas (PCL) comprise a heterogeneous group of neoplasms of mature lymphocytes with skin tropism. Although, by definition, these lymphomas are restricted to the skin at the time of diagnosis, during the course of the disease it may involve also lymph nodes and visceral organs. A close cooperation between a dermatologist and oncologist is required to ensure proper treatment. We present in a real-life data on treatment of patients with PCL between dermatology and oncology department. Material and methods. 104 patients were registered in a joined database of Oncology Department of Oncology Centre in Bydgoszcz and Dermatology Department of Medical University in Torun between 2007 and 2017. Due to different clinical and prognostic features data from MF/SS (44 patients), non-MF/SS CTCLs and CBCLs were presented separately. Results. Median overall survival for patients with MF/SS was 76.7 months. Median follow-up time was 5 years.

Purpose To determine the incidence of craniocerebral injuries in patients who experienced upper facial or midfacial traumas associated with the disorders of consciousness. To find which types of craniofacial traumas predisposed to craniocerebral injuries. To analyze a relationship between the site of the force application and the type of resultant craniocerebral injury. Materials and methods The study included 3,481 patients with upper facial and midfacial traumas. All 425 patients with craniofacial traumas and disorders of consciousness at the time of the event or hospital admission, were qualified for computed tomography (CT) of the head. Results In 85/425 patients (20%), 70 men and 15 women (age 14–71 years), craniofacial trauma coincided with a craniocerebral injury. Upper facial dislocation and zygomatic-orbital-maxillary complex fracture significantly more often co-existed with skull, dura mater or cranial nerve injuries, and zygomatico-orbital fracture with the injuries of the brain. Application of force both centrally and laterally to the horizontal plane predisposed to skull, dura mater and cranial nerve injuries. Conclusion The recommendation to perform head CT in each patient with craniofacial trauma who experienced the disorders of consciousness is as simple as possible, yet provides high diagnostic sensitivity, facilitating proper management at initial stages post-injury.

// Renata Duchnowska 1 , Piotr J. Wysocki 2 , Konstanty Korski 3 , Bogumila Czartoryska-Arlukowicz 4 , Anna Niwinska 5 , Marlena Orlikowska 6 , Barbara Radecka 7 , Maciej Studzinski 8 , Regina Demlova 9 , Barbara Ziolkowska 10 , Monika Merdalska 11 , Łukasz Hajac 12 , Paulina Myśliwiec 13 , Dorota Zuziak 14 , Sylwia Debska-Szmich 15 , Istvan Lang 16 , Malgorzata Foszczynska-Kloda 2 , Bozenna Karczmarek-Borowska 17 , Anton Żawrocki 18 , Anna Kowalczyk 18 , Wojciech Biernat 18 , Jacek Jassem 18 , for the Central and East European Oncology Group (CEEOG) 1 Military Institute of Medicine, Oncology Department, Warsaw, Poland 2 West Pomeranian Cancer Center, Szczecin, Poland 3 Greater Poland Cancer Center, Poznan, Poland 4 Bialystok Oncology Center, Bialystok, Poland 5 The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland 6 Warmia and Masuria Oncology Center, Olsztyn, Poland 7 Opole Oncology Center, Poland 8 Oncology Center, Bydgoszcz, Poland 9 Masaryk Memorial Cancer Institute, Brno, Czech Republic 10 Chemotherapy Department, Regional Hospital, Wroclaw, Poland 11 Oncology Center, Kielce, Poland 12 Oncology Center, Wroclaw, Poland 13 Oncology Center, Zielona Gora, Poland 14 Oncology Center, Bielsko-Biala, Poland 15 Medical University of Łodź, Łodź, Poland 16 Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary 17 Department of Chemotherapy, Subcarpathian Oncology Center, Rzeszow, Poland 18 Medical University of Gdansk, Gdansk, Poland Correspondence to: Renata Duchnowska, e-mail: rdtt@wp.pl Keywords: breast cancer, epidermal growth factor receptor type 2, lapatinib, mTOR, p-MAPK Received: May 19, 2015 Accepted: November 13, 2015 Published: November 24, 2015 ABSTRACT Molecular mechanisms of lapatinib resistance in breast cancer are not well understood. The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib. Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine. Immunohistochemical expression of phosphorylated adenosine monophosphate-activated protein (p-AMPK), mitogen-activated protein kinase (p-MAPK), phospho (p)-p70S6K, cyclin E, phosphatase and tensin homolog were analyzed in primary breast cancer samples. The best discriminative value for progression-free survival (PFS) was established for each biomarker and subjected to multivariate analysis. At least one biomarker was determined in 199 patients. Expression of p-p70S6K was independently associated with longer (HR 0.45; 95% CI: 0.25–0.81; p = 0.009), and cyclin E with shorter PFS (HR 1.83; 95% CI: 1.06–3.14; p = 0.029). Expression of p-MAPK (HR 1.61; 95% CI 1.13–2.29; p = 0.009) and cyclin E (HR 2.99; 95% CI: 1.29–6.94; p = 0.011) was correlated with shorter, and expression of estrogen receptor (HR 0.65; 95% CI 0.43–0.98; p = 0.041) with longer overall survival. Expression of p-AMPK negatively impacted response to treatment (HR 3.31; 95% CI 1.48–7.44; p = 0.004) and disease control (HR 3.07; 95% CI 1.25–7.58; p = 0.015). In conclusion: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways – AMPK/mTOR and Ras/Raf/MAPK. Further research is warranted to assess the clinical utility of these data and to determine a potential role of combining lapatinib with MAPK pathway inhibitors.

Introduction The aim of the study was to assess the prognostic significance of the number and type of extra nodal localizations of DLBCL as well as other factors included in IPI in the rituximab era. Materials and methods We conducted a retrospective analysis of medical documentation of 178 patients with DLBCL treated in two oncology centers between 2006 and 2011. We distinguished 3 subgroups of patients: with only nodal localization of DLBCL (A, n = 80), with 1 extra nodal site (B, n = 66) and with ≥2 extra nodal sites (C, n = 32). Results The presence and the number of extra nodal lesions did not have a prognostic impact both on the response and survival. Probabilities for OS were 79.4% ± 6, 85.5% ± 5 and 78.5% ± 8 for groups A, B and C respectively. Most common extra nodal localizations of DLBCL were: digestive duct, bones and skin. The site of involvement also did not have a prognostic significance. In a multivariate analysis negative prognostic factors for OS probability were: elevated LDH level (HR: 3.12 [95% CI: 1.3–7.47], p = 0.01) and disease stage ≥III (HR: 4.61 [95% CI: 1.32–16.1], p = 0.02). Conclusions Neither the number of extra nodal lesions nor their localization affects prognosis in patients with DLBCL in the rituximab era.

Introduction Treatment of T cell cutaneous lymphoma( CTCL) is a controversial subject and the effectiveness of treatment is still low. Aim Report of single center experience of management CTCL after progression after first line treatment. Material and methods We present 41 patients with CTCL, 29 received interferon α2b in first line, and 12 of them received second line therapy. Results Overall response rate for second line therapy was 60%. Conclusions Results of the follow-up of patients with mycosis fungoides after interferon α2b treatment failure with the literature review and discussion.

e22166 Background: Currently solid tumor response is based on anatomic measurements as defined by RECIST criteria. 18F-FLT is a PET tracer that allows imagining of cell proliferation rate. Imaging ...

639 Background: Molecular mechanisms of resistance to lapatinib are not well understood. We analyzed retrospectively expression of six potentially useful biomarkers and correlated their status with...

e19511 Background: Adding rituximab to CHOP regimen led to significant improvement in diffuse large B-cell lymphoma (DLBCL) treatment outcomes, but its role in case of extranodal DLBCL remains cont...